DSG Capital Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

DSG Capital Advisors LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 29,230 shares of the company's stock, valued at approximately $22,566,000. Eli Lilly and Company accounts for about 4.1% of DSG Capital Advisors LLC's portfolio, making the stock its 5th biggest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chancellor Financial Group WB LP bought a new position in Eli Lilly and Company in the fourth quarter worth $840,000. Thoma Capital Management LLC bought a new position in Eli Lilly and Company in the fourth quarter worth $819,000. NorthCrest Asset Manangement LLC raised its holdings in Eli Lilly and Company by 164.8% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 18,126 shares of the company's stock worth $13,993,000 after purchasing an additional 11,280 shares in the last quarter. Members Wealth LLC bought a new position in Eli Lilly and Company in the fourth quarter worth $633,000. Finally, Tableaux LLC bought a new position in Eli Lilly and Company in the fourth quarter worth $335,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $1.52 during trading hours on Thursday, reaching $720.91. 2,785,058 shares of the stock traded hands, compared to its average volume of 3,626,567. The company has a 50 day moving average price of $782.03 and a 200 day moving average price of $801.29. The firm has a market capitalization of $683.24 billion, a price-to-earnings ratio of 61.56, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LLY shares. UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.